New remote program aims to ease chemo burden for pancreatic cancer patients
NCT ID NCT05438927
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a program that provides nutrition and supportive care remotely to adults with pancreatic cancer who are receiving chemotherapy. The goal was to see if the program was easy to use and if patients were satisfied with it. 50 participants were enrolled to track how many joined and used the mobile app and support services.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
50 people
The number who actually took part.
- Started
-
Jul 2022
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ≥18 years old * Newly diagnosed metastatic or newly recurrent pancreatic cancer or locally advanced pancreatic cancer * Planning to initiate chemotherapy under the guidance of Moffitt * Able to speak and read English or Spanish * Able to provide informed consent Exclusion Criteria: * Documented or observable psychiatric or neurological disorder that would interfere with study participation (e.g., psychosis, active substance abuse) * Undergoing concurrent treatment for a second primary GI cancer * ECOG status of 2 or greater * Receipt of chemotherapy in the past 6 months for recurrent pancreatic cancer * Use of parenteral or enteral nutrition * Presence of malignant ascites * The last two exclusion criteria were included because investigators do not anticipate that these patients would benefit from additional nutrition intervention.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pancreatic cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blood test before pancreatic surgery predict a dangerous leak?
- New chemo cocktail targets pancreatic cancer at every stage
- Bacteria-Based immunotherapy targets pancreatic tumors in first human test
- Can a new radiation machine cut breath holds for cancer patients?
- Two oral drugs join chemotherapy in a bid to shrink pancreatic tumors
- Nerve-Block procedure tested against severe pancreatic and stomach cancer pain